Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 7/20 | 0.41 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.41 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.41 |
| ▸ | F10 | P00742 | 2/20 | 0.36 |
| ▸ | ST14 | Q9Y5Y6 | 2/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | PLG | P00747 | 1/20 | 0.36 |
| ▸ | PLAU | P00749 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.35 |
| ▸ | PYGL | P06737 | 1/20 | 0.34 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.33 |
| ▸ | PRCP | P42785 | 1/20 | 0.33 |
| ▸ | CLK1 | P49759 | 1/20 | 0.33 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.33 |
| ▸ | HRH2 | P25021 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16305761 | 0.93 | ACACB (0.34) | S1PR1S1PR4S1PR5PYGLPRCP | |
| SCHEMBL17834914 | 0.93 | F10 (0.37) | S1PR1S1PR4S1PR5F10ST14 | |
| SCHEMBL16305702 | 0.93 | ITGA4 (0.39) | F10ST14F2PLGPLAU | |
| SCHEMBL16305841 | 0.92 | MCL1 (0.36) | S1PR1S1PR4S1PR5MCL1PYGL | |
| SCHEMBL17834564 | 0.92 | PYGL (0.41) | S1PR1S1PR4S1PR5MCL1PYGL | |
| SCHEMBL16306158 | 0.91 | S1PR1 (0.42) | S1PR1S1PR4S1PR5PYGLHRH2 | |
| SCHEMBL16305996 | 0.91 | S1PR1 (0.40) | S1PR1S1PR5HRH2HRH1 | |
| SCHEMBL16306134 | 0.91 | PYGL (0.34) | S1PR1S1PR5PYGLPRCPHRH2 | |
| SCHEMBL16305964 | 0.91 | S1PR1 (0.38) | S1PR1S1PR5HRH2HRH1 | |
| SCHEMBL16295387 | 0.91 | S1PR1 (0.38) | S1PR1S1PR5HRH2HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3008056-B1 | NOVEL GLP-1 RECEPTOR MODULATORS | CELGENE INT II SARL (CH) | 2020-12-09 | — | — | EP | disclosed |
| US-10259823-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2019-04-16 | — | — | US | disclosed |
| US-10034886-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2018-07-31 | — | — | US | disclosed |
| US-10034886-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2018-07-31 | — | — | US | disclosed |
| US-20180021346-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2018-01-25 | — | — | US | disclosed |
| US-20170313717-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2017-11-02 | — | — | US | disclosed |
| US-9795613-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2017-10-24 | — | — | US | disclosed |
| US-9795613-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2017-10-24 | — | — | US | disclosed |
| US-20160228450-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2016-08-11 | — | — | US | disclosed |
| US-20160214993-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2016-07-28 | — | — | US | disclosed |
| WO-2016094729-A1 | GLP-1 RECEPTOR MODULATORS | CELGENE INTERNATIONAL II SARL (CH) | 2016-06-16 | — | — | WO | disclosed |
| US-20150011527-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2015-01-08 | — | — | US | disclosed |
| WO-2014201172-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS, INC. (US) | 2014-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160228450-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | S1PR1 486/4885S1PR4 665/4885S1PR5 889/4885 |
| US-20170313717-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | S1PR1 486/4885S1PR4 665/4885S1PR5 889/4885 |
| US-20160214993-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | S1PR1 486/4885S1PR4 665/4885S1PR5 889/4885 |
| US-20180021346-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | S1PR1 486/4885S1PR4 665/4885S1PR5 889/4885 |
| US-10034886-B2 | GLP-1 receptor modulators | GLP1R, GIPR, GCGR | S1PR1 523/4885S1PR4 713/4885S1PR5 939/4885 |
| US-10259823-B2 | GLP-1 receptor modulators | GLP1R, GIPR, GCGR | S1PR1 523/4885S1PR4 713/4885S1PR5 939/4885 |
| US-20150011527-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | S1PR1 486/4885S1PR4 665/4885S1PR5 889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.